Dear visitor of scilifelab.se

If this is your first visit to the website, we would like to ask for your help so we can improve the website navigation. Our aim is to make it easier for you and your colleagues to find the support you are looking for when you visit scilifelab.se in the near future. Please follow the link to our survey and answer the questions, it only takes 5 minutes.

Medicinal Chemistry – Lead Identification

National facility

Medicinal Chemistry – Lead Identification 600x200pxl

The Medicinal Chemistry - Lead Identification facility will take on, explore, and optimize molecules in drug discovery projects. Synthetic and computational chemistry will be at the core of the so-called Design-Make-Test-Analyze cycle that characterizes a small molecule drug discovery program. The mission is to deliver small drug-like molecules with potency, selectivity, physicochemical and ADMET properties of sufficient quality to allow proof-of-concept animal studies. We work in close collaboration with our colleges in the hit-to lead facility https://www.scilifelab.se/facilities/hit2lead/.

SERVICES

 

  • Organic synthesis of bioactive compounds (small molecules and peptides).
  • Medicinal chemistry expertize.
  • Iterative design, synthesis and analysis of assay data to improve compound properties.
  • Compound characterization, structure determination and purity analysis.
  • Quantitative structure based activity relationships.
  • Scale-up synthesis of bioactive compounds.
  • Selection and purchase of commercial compounds.
  • Synthesis of reference compounds.
  • Competitive Intelligence
  • In collaboration with Medicinal chemistry Hit2Lead
    • Computer-based drug design

EQUIPMENT

 

  • Analytical UHPLC-MS.
  • Automated flash chromatography systems.
  • GCMS instruments.
  • Hardware and software for Computer-Aided Drug Design.
  • Microwave batch reactors.
  • Microwave continuous flow reactors.
  • NMR spectrometers.
  • Peptide synthesizer.
  • Preparative HPLC instruments.

RECENT PROJECTS

 

R. Isaksson, I. Kumpiņa, J. Sävmarker, M. Larhed, J. Wannberg*: Rapid and straightforward transesterification of sulfonyl carbamates. Tetrahedron Lett 57 (2016) 1476-1478. .DOI 10.1016/j.tetlet.2016.02.071

I. Kumpiņa, R. Isaksson, J. Sävmarker, J. Wannberg, M. Larhed*: Microwave Promoted Transcarbamylation Reaction of Sulfonylcarbamates under Continuous-Flow Conditions. Org. Process Res. Dev.20 (2016) 440-445.DOI 10.1021/acs.oprd.5b00323

P. Wakchaure, U. Bremberg, J. Wannberg, M. Larhed*: Synthesis of enantiopure angiotensin II type 2 receptor [AT2R] antagonist EMA401. Tetrahedron 71 (2015), 6881-6887. DOI: 10.1016/j.tet.2015.07.08

A. Jansson, A. Więckowska, C. Björkelid, S. Yahiaoui, S. Sooriyaarachchi, M. Lindh, T. Bergfors, S. Dharavath, M. Desroses, S. Suresh, M. Andaloussi, R. Nikhil, S. Sreevalli, B. Srinivasa, M. Larhed, T. A. Jones, A. Karlén*, S. L. Mowbray*: DXR inhibition by potent mono- and disubstituted fosmidomycin analogues. J. Med. Chem. 56 (2013), 6190-6199. DOI: 10.1021/jm4006498

J. Gising, M. T. Nilsson, L. Odell, S. Yahiaoui, M. Lindh, H. Iyer, B. R. Srinivasa,  M. Larhed, S. L. Mowbray, A. Karlén*: Tri-Substituted Imidazoles as Mycobacterium tuberculosis Glutamine-Synthetase Inhibitors. J. Med. Chem. 55 (2012). 2894−2898. DOI: 10.1021/jm201212h